GILD: Diversified pipeline advances in HIV, oncology, and inflammation set up multiple launches and key data
The company is advancing a diversified pipeline across virology, oncology, and inflammation, with multiple new launches and promising clinical data expected in the next year. Key assets include long-acting HIV regimens, novel cell therapies, ADCs, and innovative inflammation treatments.Based on Gil…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.